Jpmorgan Chase & CO Catalent, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Catalent, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,320,881 shares of CTLT stock, worth $77.5 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,320,881
Previous 1,185,712
11.4%
Holding current value
$77.5 Million
Previous $66.9 Million
10.97%
% of portfolio
0.01%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding CTLT
# of Institutions
486Shares Held
160MCall Options Held
364KPut Options Held
837K-
Vanguard Group Inc Valley Forge, PA20.4MShares$1.2 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY15.4MShares$901 Million0.02% of portfolio
-
Nomura Holdings Inc Tokyo, M011MShares$645 Million1.22% of portfolio
-
State Street Corp Boston, MA7.34MShares$431 Million0.02% of portfolio
-
Barclays PLC London, X04.97MShares$291 Million0.09% of portfolio
About Catalent, Inc.
- Ticker CTLT
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 179,896,000
- Market Cap $10.6B
- Description
- Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...